SI3219328T1 - Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe - Google Patents
Človeška protitelesa proti-IL-23, sestavki, postopki in uporabeInfo
- Publication number
- SI3219328T1 SI3219328T1 SI200632385T SI200632385T SI3219328T1 SI 3219328 T1 SI3219328 T1 SI 3219328T1 SI 200632385 T SI200632385 T SI 200632385T SI 200632385 T SI200632385 T SI 200632385T SI 3219328 T1 SI3219328 T1 SI 3219328T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antibodies
- compositions
- human anti
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75488905P | 2005-12-29 | 2005-12-29 | |
EP17156111.1A EP3219328B1 (en) | 2005-12-29 | 2006-12-28 | Human anti-il-23 antibodies, compositions, method and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3219328T1 true SI3219328T1 (sl) | 2020-10-30 |
Family
ID=38218878
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200632156A SI2548577T1 (sl) | 2005-12-29 | 2006-12-28 | Človeška protitelesa proti il-23, sestavki, postopki in uporabe |
SI200631828T SI1971366T1 (sl) | 2005-12-29 | 2006-12-28 | Humana protitelesa anti-il-23, sestavki, postopki in uporabe |
SI200632385T SI3219328T1 (sl) | 2005-12-29 | 2006-12-28 | Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200632156A SI2548577T1 (sl) | 2005-12-29 | 2006-12-28 | Človeška protitelesa proti il-23, sestavki, postopki in uporabe |
SI200631828T SI1971366T1 (sl) | 2005-12-29 | 2006-12-28 | Humana protitelesa anti-il-23, sestavki, postopki in uporabe |
Country Status (37)
Country | Link |
---|---|
US (9) | US7935344B2 (sl) |
EP (4) | EP1971366B1 (sl) |
JP (1) | JP5193881B2 (sl) |
KR (1) | KR101210395B1 (sl) |
CN (2) | CN102887954B (sl) |
AU (1) | AU2006330411B2 (sl) |
BR (1) | BRPI0620946B8 (sl) |
CA (1) | CA2635692C (sl) |
CR (1) | CR10181A (sl) |
CY (4) | CY1115935T1 (sl) |
DK (3) | DK3219328T3 (sl) |
EA (2) | EA019476B9 (sl) |
EC (1) | ECSP088591A (sl) |
ES (3) | ES2517420T3 (sl) |
GT (1) | GT200800132A (sl) |
HK (1) | HK1124548A1 (sl) |
HN (1) | HN2008000988A (sl) |
HR (3) | HRP20140982T1 (sl) |
HU (3) | HUE034269T2 (sl) |
IL (5) | IL192458A (sl) |
LT (3) | LT2548577T (sl) |
LU (1) | LUC00071I2 (sl) |
MX (2) | MX2008008621A (sl) |
MY (2) | MY162559A (sl) |
NI (1) | NI200800193A (sl) |
NL (1) | NL300935I2 (sl) |
NO (4) | NO343345B1 (sl) |
NZ (1) | NZ569546A (sl) |
PL (3) | PL1971366T3 (sl) |
PT (3) | PT1971366E (sl) |
RS (3) | RS53685B1 (sl) |
SG (1) | SG10201505755YA (sl) |
SI (3) | SI2548577T1 (sl) |
SV (1) | SV2008002972A (sl) |
UA (1) | UA101301C2 (sl) |
WO (1) | WO2007076524A2 (sl) |
ZA (1) | ZA200806556B (sl) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
JP2009501006A (ja) | 2005-06-30 | 2009-01-15 | セントカー・インコーポレーテツド | 抗il−23抗体、組成物、方法および用途 |
DK1937721T3 (da) * | 2005-08-25 | 2010-10-18 | Lilly Co Eli | Anti-IL-23 antistoffer |
DK1931710T3 (en) | 2005-08-31 | 2017-04-03 | Merck Sharp & Dohme | CONSTRUCTED ANTI-IL-23 ANTIBODIES |
CA2621086A1 (en) | 2005-09-01 | 2007-03-08 | Schering Corporation | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease |
PL1971366T3 (pl) * | 2005-12-29 | 2015-01-30 | Janssen Biotech Inc | Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
CA2655372A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
CA2678863A1 (en) | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
NZ579158A (en) | 2007-02-23 | 2012-01-12 | Schering Corp | Engineered anti-il-23p19 antibodies |
NZ579297A (en) | 2007-02-28 | 2012-03-30 | Schering Corp | Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders |
EP2666783B1 (en) | 2007-09-25 | 2019-06-26 | Genzyme Corporation | Compositions for inhibiting interleukin-23 pathways |
EP2215125A1 (en) | 2007-11-27 | 2010-08-11 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
PL2708558T3 (pl) | 2008-04-11 | 2018-09-28 | Chugai Seiyaku Kabushiki Kaisha | Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny |
CN102202655B (zh) * | 2008-08-27 | 2013-06-19 | 默沙东公司 | 基因工程抗IL-23p19抗体的冻干制剂 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
WO2010036226A1 (en) * | 2008-09-26 | 2010-04-01 | George Nelson | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis |
MX2011003277A (es) * | 2008-10-14 | 2012-09-21 | Salubrious Pharmaceuticals LLC | Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral. |
CA2745218A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Feed supplement for mammalian cell culture and methods of use |
WO2011017294A1 (en) | 2009-08-07 | 2011-02-10 | Schering Corporation | Human anti-rankl antibodies |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
BR112012010280B1 (pt) * | 2009-10-30 | 2020-09-24 | Janssen Biotech, Inc. | Anticorpo isolado ou fragmento do mesmo que se liga especificamente a il-17a humana, seu uso, e composição farmacêutica |
GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
ES2776980T3 (es) | 2009-12-23 | 2020-08-03 | Merck Sharp & Dohme | Línea celular 3M |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
BR112013009083B1 (pt) * | 2010-10-13 | 2021-08-10 | Janssen Biotech, Inc. | Anticorpos humanos para oncostatina m, seu processo de fabricação, fragmento de ligação a antígeno, composição farmacêutica, polinucleotídeo isolado, célula hospedeira recombinante estavelmente transformada ou transfectada |
RS55161B1 (sr) | 2010-11-04 | 2017-01-31 | Boehringer Ingelheim Int | Anti-il-23 antitela |
WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
CA2827923C (en) | 2011-02-25 | 2021-11-23 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc antibody |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
NZ700802A (en) | 2012-05-03 | 2017-06-30 | Boehringer Ingelheim Int | Anti-il-23p19 antibodies |
WO2014004436A2 (en) | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
AU2013352260A1 (en) * | 2012-11-29 | 2015-06-11 | Bayer Healthcare Llc | Humanized monoclonal antibodies against activated protein C and uses thereof |
UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
US9113892B2 (en) | 2013-01-08 | 2015-08-25 | Covidien Lp | Surgical clip applier |
AR094877A1 (es) * | 2013-03-08 | 2015-09-02 | Lilly Co Eli | Anticuerpos que se unen a il-23 |
EP2968486A1 (en) * | 2013-03-15 | 2016-01-20 | Amgen Inc. | Methods for treating crohn's disease using an anti-il23 antibody |
EP2968488A1 (en) | 2013-03-15 | 2016-01-20 | Amgen Inc. | Methods for treating psoriasis using an anti-il-23 antibody |
CN105408356A (zh) | 2013-05-10 | 2016-03-16 | 努玛有限公司 | 双特异性构建体及其用于治疗多种疾病的用途 |
CN105007895B (zh) | 2013-11-22 | 2017-11-17 | 玫琳凯有限公司 | 用于敏感皮肤的组合物 |
WO2015114426A2 (en) * | 2014-01-30 | 2015-08-06 | Massimo Zanotti | A method for monitoring the respect of well-being of live poultry intended for slaughter |
CN106535889A (zh) | 2014-02-10 | 2017-03-22 | 帕塔拉制药有限责任公司 | 用于治疗肺疾病的肥大细胞稳定剂 |
CN106456595A (zh) | 2014-02-10 | 2017-02-22 | 帕塔拉制药有限责任公司 | 用于系统性病症的肥大细胞稳定剂治疗 |
EP3708679A1 (en) | 2014-07-24 | 2020-09-16 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
TWI711629B (zh) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
PE20221834A1 (es) | 2014-12-19 | 2022-11-29 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina |
SI3233921T1 (sl) | 2014-12-19 | 2022-01-31 | Chugai Seiyaku Kabushiki Kaisha | Protitelesa proti C5 in postopki za uporabo |
EP3253794A1 (en) | 2015-02-04 | 2017-12-13 | Boehringer Ingelheim International GmbH | Methods of treating inflammatory diseases |
CA2974547A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof |
US10774148B2 (en) | 2015-02-27 | 2020-09-15 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
MX2017013156A (es) | 2015-04-14 | 2018-02-21 | Boehringer Ingelheim Int | Metodos para tratar enfermedades. |
US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
WO2017027387A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
CN108290058B (zh) | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
TWI811716B (zh) | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
WO2017087391A1 (en) | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
WO2017112536A1 (en) | 2015-12-22 | 2017-06-29 | Amgen Inc. | Ccl20 as a predictor of clinical response to il23-antagonists |
WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
AU2017241776A1 (en) | 2016-03-29 | 2018-10-11 | Janssen Biotech, Inc. | Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody |
EP3560956A3 (en) | 2016-04-15 | 2020-01-01 | Boehringer Ingelheim International GmbH | Methods of treating inflammatory diseases |
MX2019001448A (es) | 2016-08-05 | 2019-09-13 | Chugai Pharmaceutical Co Ltd | Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8). |
WO2018044942A1 (en) | 2016-08-31 | 2018-03-08 | Patara Pharma, LLC | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
WO2018064436A1 (en) * | 2016-09-30 | 2018-04-05 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il23 specific antibody |
WO2018067341A1 (en) | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Cromolyn compositions for treatment of pulmonary fibrosis |
WO2018071504A2 (en) | 2016-10-14 | 2018-04-19 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
JP2020502261A (ja) | 2016-11-16 | 2020-01-23 | ヤンセン バイオテツク,インコーポレーテツド | 抗il23特異的抗体で乾癬を治療する方法 |
US11840565B2 (en) | 2016-12-29 | 2023-12-12 | University Of Miami | Methods and compositions for treating virus-associated inflammation |
EP3574010A4 (en) | 2017-01-30 | 2020-12-16 | Chugai Seiyaku Kabushiki Kaisha | ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE |
WO2018204374A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3459968A1 (en) * | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
US20190269757A1 (en) * | 2018-03-05 | 2019-09-05 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
TWI744617B (zh) | 2018-03-30 | 2021-11-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
EP3790587A4 (en) | 2018-05-11 | 2022-01-26 | Janssen Biotech, Inc. | METHOD OF TREATMENT OF DEPRESSION USING IL-23 ANTIBODIES |
KR20210032441A (ko) | 2018-07-13 | 2021-03-24 | 아스트라제네카 콜라보레이션 벤처스, 엘엘씨 | 브라지쿠맙을 이용한 궤양성 대장염의 치료 |
US20200025776A1 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody |
MX2021005905A (es) | 2018-11-20 | 2021-06-23 | Janssen Biotech Inc | Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23. |
WO2020108530A1 (zh) * | 2018-11-27 | 2020-06-04 | 信达生物制药(苏州)有限公司 | 抗IL-23p19抗体及其用途 |
WO2020128864A1 (en) | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
KR20210141990A (ko) | 2019-03-14 | 2021-11-23 | 얀센 바이오테크 인코포레이티드 | 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법 |
AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
CN110564694B (zh) * | 2019-09-23 | 2021-07-13 | 华东师范大学 | 分泌il-23抗体的靶向前列腺癌的car-t细胞药物 |
WO2021126435A1 (en) | 2019-12-20 | 2021-06-24 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
KR20230006551A (ko) * | 2020-05-05 | 2023-01-10 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 크론병을 치료하는 방법 |
CN111718414B (zh) * | 2020-06-12 | 2021-03-02 | 江苏荃信生物医药有限公司 | 抗人白介素23单克隆抗体及其应用 |
TW202224702A (zh) | 2020-09-10 | 2022-07-01 | 美商美國禮來大藥廠 | 治療性抗體調配物 |
BR112023018400A2 (pt) * | 2021-03-12 | 2023-12-12 | Janssen Biotech Inc | Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23 |
KR20230156387A (ko) | 2021-03-12 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체에 의해 건선성 관절염을 치료하는 안전하고 효과적인 방법 |
EP4347018A1 (en) | 2021-05-28 | 2024-04-10 | Eli Lilly and Company | Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis |
AU2022306973A1 (en) | 2021-07-09 | 2024-02-22 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-il12/il23 antibody compositions |
CN115785267B (zh) * | 2021-09-10 | 2023-12-15 | 三优生物医药(上海)有限公司 | 一种靶向IL-23p19的抗体或其抗原结合片段及其应用 |
WO2023056417A1 (en) | 2021-09-30 | 2023-04-06 | Eli Lilly And Company | Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis |
TW202323304A (zh) * | 2021-09-30 | 2023-06-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗il23抗體融合蛋白及用途 |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US20230151087A1 (en) * | 2021-11-15 | 2023-05-18 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
WO2023095000A1 (en) | 2021-11-23 | 2023-06-01 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
US20230212280A1 (en) * | 2021-12-17 | 2023-07-06 | Janssen Biotech, Inc. | IL-23 Specific Antibodies for the Treatment of Systemic Sclerosis |
US20230312703A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of Treating Psoriasis with IL-23 Specific Antibody |
US20230374122A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody |
WO2024073588A1 (en) * | 2022-09-28 | 2024-04-04 | Board Of Regents, The University Of Texas System | Respiratory dry powder delivery |
WO2024077113A1 (en) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Methods of treating fatigue in ulcerative colitis |
Family Cites Families (166)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
GB2097032B (en) | 1981-04-22 | 1984-09-19 | Teron International Urban Dev | A combined ceiling air and services distribution system mechanical chasse and structural roof member |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
DE3546807C2 (sl) | 1985-03-30 | 1991-03-28 | Marc Genf/Geneve Ch Ballivet | |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
EP0318512B1 (en) | 1986-08-18 | 1998-06-17 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
DE3888224T2 (de) | 1987-04-24 | 1994-07-21 | Teijin Ltd | Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung. |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US4939666A (en) | 1987-09-02 | 1990-07-03 | Genex Corporation | Incremental macromolecule construction methods |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
DE3909708A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
EP0478627A4 (en) | 1989-05-16 | 1992-08-19 | William D. Huse | Co-expression of heteromeric receptors |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
DE10399036I1 (de) | 1989-08-07 | 2004-04-01 | Peptide Technology Ltd | Bindeligande für Tumornekrosisfaktor. |
AU638762B2 (en) | 1989-10-05 | 1993-07-08 | Optein Inc | Cell-free synthesis and isolation of novel genes and polypeptides |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
JP3112463B2 (ja) * | 1990-03-27 | 2000-11-27 | 雪印乳業株式会社 | モノクローナル抗体の作製方法 |
TW212184B (sl) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
AU8081491A (en) | 1990-06-01 | 1991-12-31 | Cetus Corporation | Compositions and methods for identifying biologically active molecules |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
ATE204902T1 (de) | 1990-06-29 | 2001-09-15 | Large Scale Biology Corp | Melaninproduktion durch transformierte mikroorganismen |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
GB9022648D0 (en) | 1990-10-18 | 1990-11-28 | Charing Cross Sunley Research | Polypeptide and its use |
DE69128253T2 (de) | 1990-10-29 | 1998-06-18 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
CA2104698A1 (en) | 1991-02-21 | 1992-08-22 | John J. Toole | Aptamers specific for biomolecules and methods of making |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
KR100246082B1 (ko) | 1991-07-02 | 2000-04-01 | 인헤일, 인코오포레이티드 | 에어로졸화된약제를전달하는방법및장치 |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
DE4207475A1 (de) | 1992-03-10 | 1993-09-16 | Goldwell Ag | Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
AU4829593A (en) | 1992-09-23 | 1994-04-12 | Fisons Plc | Inhalation device |
AU5322494A (en) | 1992-10-02 | 1994-04-26 | Trustees Of Dartmouth College | Bispecific reagents for redirected targeting of low density lipoprotein |
SK51695A3 (en) | 1992-10-19 | 1995-11-08 | Dura Pharma Inc | Dry powder medicament inhaler |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
DE69414369T2 (de) | 1993-01-19 | 1999-05-27 | Glaxo Group Ltd | Aerosol-spender und verfahren zu seiner herstellung |
CA2155728C (en) | 1993-02-12 | 2000-04-25 | Gerald R. Crabtree | Regulated transcription of targeted genes and other biological events |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
AU692239B2 (en) | 1994-03-07 | 1998-06-04 | Medarex, Inc. | Bispecific molecules having clinical utilities |
US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
BR9612410A (pt) | 1996-01-03 | 1999-07-13 | Glaxo Group Ltd | Aparelho para inalação |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
EP0826695B1 (de) | 1996-09-03 | 2001-12-12 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
CO4810232A1 (es) | 1997-07-25 | 1999-06-30 | Schering Corp | Citoquinas de mamiferos y sus secuencias codificadoras |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
ATE238035T1 (de) | 1997-09-29 | 2003-05-15 | Inhale Therapeutic Syst | Perforierte mikropartikel und deren verwendung |
AU2661199A (en) | 1998-02-06 | 1999-08-23 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
AU3170199A (en) | 1998-04-14 | 1999-11-08 | Chugai Research Institute For Molecular Medicine, Inc. | Novel cytokine-like protein |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
WO2000009552A1 (en) | 1998-08-14 | 2000-02-24 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US6800460B1 (en) | 1999-03-11 | 2004-10-05 | Schering Corporation | Mammalian cytokine complexes |
AR022890A1 (es) | 1999-03-11 | 2002-09-04 | Schering Corp | Citoquinas mamiferas; reactivos relacionados y metodos |
AU5151100A (en) | 1999-05-19 | 2000-12-05 | Incyte Genomics, Inc. | Extracellular signaling molecules |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
WO2001018051A2 (en) | 1999-09-09 | 2001-03-15 | Schering Corporation | Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions |
GB0001448D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
US20030139327A9 (en) | 2000-01-31 | 2003-07-24 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
NZ522146A (en) | 2000-05-10 | 2004-10-29 | Schering Corp | Mammalian receptor-like proteins, designated DNAX cytokine receptor subunits (DCRS), in particular DCRS5 |
WO2002079255A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceuticals Corporation | RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
ITPD20010108A1 (it) | 2001-05-08 | 2002-11-08 | Fidia Advanced Biopolymers Srl | Biomateriali polimerici elettricamente conduttori, loro processo di preparazione ed impiego nel settore biomedico sanitario. |
WO2003011878A2 (en) | 2001-08-03 | 2003-02-13 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
NZ539271A (en) | 2002-10-30 | 2008-12-24 | Genentech Inc | Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23) |
CN100434440C (zh) * | 2002-12-02 | 2008-11-19 | 阿布格尼克斯公司 | 针对肿瘤坏死因子的抗体及其用途 |
EP1587834B1 (en) | 2002-12-23 | 2011-07-06 | Schering Corporation | Uses of il-23 mammalian cytokine; related reagents |
US20040219150A1 (en) | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
KR20050110628A (ko) * | 2003-02-10 | 2005-11-23 | 엘란 파마슈티칼스, 인크. | 면역글로불린 제제 및 이의 제조방법 |
WO2004081190A2 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Uses of il-23 agonists and antagonists; related reagents |
US20040185506A1 (en) * | 2003-03-21 | 2004-09-23 | Heavner George A. | Epitope mapping using nuclear magnetic resonance |
CN101052726A (zh) * | 2003-05-09 | 2007-10-10 | 森托科尔公司 | IL-23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途 |
WO2005005604A2 (en) | 2003-06-30 | 2005-01-20 | Centocor, Inc. | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
ES2541489T3 (es) * | 2004-02-06 | 2015-07-21 | Morphosys Ag | Anticuerpos humanos anti-CD38 y usos para ellos |
BRPI0507794A (pt) | 2004-02-17 | 2007-07-17 | Schering Corp | métodos de modular a atividade de il-23, reagentes relacionados |
MXPA06012754A (es) | 2004-05-03 | 2007-02-19 | Schering Corp | El uso de la expresion de il-17 para predecir la inflamacion de la piel: metodos de tratamiento. |
WO2005108425A1 (en) * | 2004-05-10 | 2005-11-17 | Cytos Biotechnology Ag | Il-23 p19 antigen array and uses thereof |
AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
US20060194981A1 (en) * | 2005-02-26 | 2006-08-31 | Jass Paul A | Process for preparation of probucol derivatives |
JP2009501006A (ja) | 2005-06-30 | 2009-01-15 | セントカー・インコーポレーテツド | 抗il−23抗体、組成物、方法および用途 |
DK1937721T3 (da) | 2005-08-25 | 2010-10-18 | Lilly Co Eli | Anti-IL-23 antistoffer |
DK1931710T3 (en) | 2005-08-31 | 2017-04-03 | Merck Sharp & Dohme | CONSTRUCTED ANTI-IL-23 ANTIBODIES |
PL1971366T3 (pl) * | 2005-12-29 | 2015-01-30 | Janssen Biotech Inc | Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
JP6136279B2 (ja) | 2013-01-15 | 2017-05-31 | 株式会社ジェイテクト | 転がり軸受装置 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
US9353645B1 (en) | 2015-02-16 | 2016-05-31 | Borgwarner Inc. | Vane ring thermal strain relief cuts |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2006
- 2006-12-28 PL PL06846836T patent/PL1971366T3/pl unknown
- 2006-12-28 RS RS20140565A patent/RS53685B1/en unknown
- 2006-12-28 PT PT68468362T patent/PT1971366E/pt unknown
- 2006-12-28 PT PT171561111T patent/PT3219328T/pt unknown
- 2006-12-28 RS RS20170468A patent/RS55963B1/sr unknown
- 2006-12-28 LT LTEP12174197.9T patent/LT2548577T/lt unknown
- 2006-12-28 DK DK17156111.1T patent/DK3219328T3/da active
- 2006-12-28 RS RS20200911A patent/RS60616B1/sr unknown
- 2006-12-28 PT PT121741979T patent/PT2548577T/pt unknown
- 2006-12-28 EP EP06846836.2A patent/EP1971366B1/en active Active
- 2006-12-28 EA EA200870129A patent/EA019476B9/ru active Protection Beyond IP Right Term
- 2006-12-28 MX MX2008008621A patent/MX2008008621A/es active IP Right Grant
- 2006-12-28 SG SG10201505755YA patent/SG10201505755YA/en unknown
- 2006-12-28 EP EP12174197.9A patent/EP2548577B1/en active Active
- 2006-12-28 EP EP20180279.0A patent/EP3760230A1/en active Pending
- 2006-12-28 PL PL12174197T patent/PL2548577T3/pl unknown
- 2006-12-28 HU HUE12174197A patent/HUE034269T2/en unknown
- 2006-12-28 US US11/617,503 patent/US7935344B2/en active Active
- 2006-12-28 SI SI200632156A patent/SI2548577T1/sl unknown
- 2006-12-28 WO PCT/US2006/062674 patent/WO2007076524A2/en active Application Filing
- 2006-12-28 JP JP2008548853A patent/JP5193881B2/ja active Active
- 2006-12-28 CN CN201210297501.1A patent/CN102887954B/zh active Active
- 2006-12-28 EP EP17156111.1A patent/EP3219328B1/en active Active
- 2006-12-28 DK DK12174197.9T patent/DK2548577T3/en active
- 2006-12-28 BR BRPI0620946A patent/BRPI0620946B8/pt active IP Right Grant
- 2006-12-28 MY MYPI2011001645A patent/MY162559A/en unknown
- 2006-12-28 AU AU2006330411A patent/AU2006330411B2/en active Active
- 2006-12-28 SI SI200631828T patent/SI1971366T1/sl unknown
- 2006-12-28 UA UAA200809846A patent/UA101301C2/ru unknown
- 2006-12-28 SI SI200632385T patent/SI3219328T1/sl unknown
- 2006-12-28 PL PL17156111T patent/PL3219328T3/pl unknown
- 2006-12-28 ES ES06846836.2T patent/ES2517420T3/es active Active
- 2006-12-28 NZ NZ569546A patent/NZ569546A/en unknown
- 2006-12-28 DK DK06846836.2T patent/DK1971366T3/da active
- 2006-12-28 ES ES12174197.9T patent/ES2622602T3/es active Active
- 2006-12-28 CA CA2635692A patent/CA2635692C/en active Active
- 2006-12-28 ES ES17156111T patent/ES2807928T3/es active Active
- 2006-12-28 CN CN2006800535467A patent/CN101389351B/zh active Active
- 2006-12-28 HU HUE17156111A patent/HUE049832T2/hu unknown
- 2006-12-28 EA EA201301072A patent/EA035459B1/ru unknown
- 2006-12-28 MY MYPI20082401A patent/MY163032A/en unknown
- 2006-12-28 KR KR1020087018522A patent/KR101210395B1/ko active IP Right Grant
- 2006-12-28 LT LTEP17156111.1T patent/LT3219328T/lt unknown
-
2008
- 2008-06-26 IL IL192458A patent/IL192458A/en active IP Right Grant
- 2008-06-27 HN HN2008000988A patent/HN2008000988A/es unknown
- 2008-06-27 SV SV2008002972A patent/SV2008002972A/es unknown
- 2008-06-27 NI NI200800193A patent/NI200800193A/es unknown
- 2008-06-30 MX MX2012006997A patent/MX342595B/es unknown
- 2008-06-30 EC EC2008008591A patent/ECSP088591A/es unknown
- 2008-07-01 GT GT200800132A patent/GT200800132A/es unknown
- 2008-07-23 NO NO20083266A patent/NO343345B1/no active Protection Beyond IP Right Term
- 2008-07-28 ZA ZA200806556A patent/ZA200806556B/xx unknown
- 2008-07-29 CR CR10181A patent/CR10181A/es not_active Application Discontinuation
-
2009
- 2009-03-18 HK HK09102604.5A patent/HK1124548A1/xx unknown
-
2010
- 2010-08-12 US US12/855,354 patent/US7993645B2/en active Active
-
2011
- 2011-04-04 US US13/079,457 patent/US8106177B2/en active Active
- 2011-06-30 US US13/173,090 patent/US8221760B2/en active Active
-
2012
- 2012-05-20 IL IL219890A patent/IL219890A/en active IP Right Grant
- 2012-06-15 US US13/524,122 patent/US9353181B2/en active Active
-
2014
- 2014-10-14 HR HRP20140982TT patent/HRP20140982T1/hr unknown
- 2014-10-29 CY CY20141100889T patent/CY1115935T1/el unknown
- 2014-12-24 IL IL236427A patent/IL236427A/en active IP Right Grant
-
2016
- 2016-04-29 US US15/142,765 patent/US9783607B2/en active Active
- 2016-11-13 IL IL248917A patent/IL248917A0/en unknown
-
2017
- 2017-05-04 HR HRP20170675TT patent/HRP20170675T1/hr unknown
- 2017-05-04 CY CY20171100485T patent/CY1118880T1/el unknown
- 2017-09-01 US US15/694,107 patent/US10030070B2/en active Active
-
2018
- 2018-04-16 IL IL258718A patent/IL258718A/en unknown
- 2018-04-25 LU LU00071C patent/LUC00071I2/fr unknown
- 2018-04-26 NL NL300935C patent/NL300935I2/nl unknown
- 2018-05-02 HU HUS1800021C patent/HUS1800021I1/hu unknown
- 2018-05-07 CY CY2018013C patent/CY2018013I1/el unknown
- 2018-05-08 LT LTPA2018010C patent/LTC1971366I2/lt unknown
- 2018-06-20 US US16/013,141 patent/US10954297B2/en active Active
-
2019
- 2019-01-04 NO NO20190011A patent/NO344118B1/no unknown
- 2019-07-10 NO NO2019029C patent/NO2019029I1/no unknown
- 2019-08-16 NO NO20190992A patent/NO20190992A1/no unknown
-
2020
- 2020-08-03 HR HRP20201215TT patent/HRP20201215T1/hr unknown
- 2020-08-31 CY CY20201100813T patent/CY1123400T1/el unknown
-
2021
- 2021-02-22 US US17/181,778 patent/US20210188966A1/en active Granted
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1800021I1 (hu) | Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások | |
HRP20190220T1 (hr) | Anti-il-23 protutijela, pripravci, postupci i upotrebe | |
HK1208035A1 (en) | Anti-il-6 antibodies, compositions, methods and uses -il-6 | |
EP1784425A4 (en) | ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES | |
IL187459A0 (en) | Anti - mcp-1 antibodies, compositions, methods and uses | |
GB0502889D0 (en) | Novel method and compositions |